Send to

Choose Destination
Oncotarget. 2018 Jan 3;9(11):9789-9807. doi: 10.18632/oncotarget.23929. eCollection 2018 Feb 9.

Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma.

Author information

Lund University, Faculty of Medicine, Department of Clinical Sciences Lund (Surgery), Lund, Sweden.
Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Lund University, Skane University Hospital, Department of Clinical Sciences Lund (Surgery), Lund, Sweden.
Department of Experimental Design and Bioinformatics, Warsaw University of Life Sciences, Warsaw, Poland.
Department of Translational Medicine, Lund University, Malmö, Sweden.
Department of Pathology, Skåne University Hospital, Lund, Sweden.
Lund University, Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund, Sweden.
Department of Biomedical Engineering, Clinical Protein Science and Imaging, Lund University, Lund, Sweden.


Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Here we show that shotgun and targeted protein sequencing can be used to identify potential prognostic biomarkers in formalin-fixed paraffin-embedded specimens from 9 patients with PDAC with "short" survival (<12 months) and 10 patients with "long" survival (>45 months) undergoing surgical resection. A total of 24 and 147 proteins were significantly upregulated [fold change ≥2 or ≤0.5 and P<0.05; or different detection frequencies (≥5 samples)] in patients with "short" survival (including GLUT1) and "long" survival (including C9orf64, FAM96A, CDH1 and CDH17), respectively. STRING analysis of these proteins indicated a tight protein-protein interaction network centered on TP53. Ingenuity pathway analysis linked proteins representing "activated stroma factors" and "basal tumor factors" to poor prognosis of PDAC. It also highlighted TCF1 and CTNNB1 as possible upstream regulators. Further parallel reaction monitoring verified that seven proteins were upregulated in patients with "short" survival (MMP9, CLIC3, MMP8, PRTN3, P4HA2, THBS1 and FN1), while 18 proteins were upregulated in patients with "long" survival, including EPCAM, LGALS4, VIL1, CLCA1 and TPPP3. Thus, we verified 25 protein biomarker candidates for PDAC prognosis at the tissue level. Furthermore, an activated stroma status and protein-protein interactions with TP53 might be linked to poor prognosis of PDAC.


biomarker; pancreatic ductal adenocarcinoma; proteome; survival; tumor microenvironment

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center